Pharmaceutical Nanotechnology - Volume 11, Issue 1, 2023

Insulin is a peptide hormone released by pancreatic beta cells. An autoimmune reaction in diabetes mellitus type 1 causes the beta cells to die, preventing insulin from being produced or released into the bloodstream; that impacts 30 million people globally and is linked to shortened lifespan due to acute and chronic repercussions. Insulin therapy aims to replicate normal pancreatic insulin secretion, which includes low levels of insulin that are always present to support basic metabolism, as well as the two-phase secretion of additional insulin in response to high blood sugar - an initial spike in secreted insulin, followed by an extended period of continued insulin secretion. This is performed by combining various insulin formulations at varying rates and lengths of time. Since the beginning of human insulin use, several advances in insulin formulations have been made to help meet these aims as much as possible, resulting in improved glycaemic control while limiting hypoglycemia. In this review, we looked at devices used by patients with type 1 diabetes, such as insulin pumps, continuous glucose monitors, and, more recently, systems that combine a pump with a monitor for algorithm-driven insulin administration automation. We intend to provide insight into supplementary therapies and nanotechnology employed in insulin therapy as a result of our review.

Recent advances in electrospinning have transformed the process of fabricating ultrafine nano-fiber scaffolds with side benefits to drug delivery systems and delivery systems in general. The extremely thin quality of electrospun nanofiber scaffolds, along with an effective area of high specificity and a stereological porous structure, capacitates them for the delivery of biomolecules, genes, and drugs. Accordingly, the present study gives a close preface on certain approaches to incorporating drugs and biomolecules into an electrospun nanofiber scaffold, including blending, surface engineering and modification, coaxial electrospinning and emulsion-based systems. The study further elaborates on certain biomedical applications of nanofibers as drug delivery systems, with case examples of Transdermal systems/ antibacterial agents/ wound dressing, cancer treatment, scaffolds for Growth Factor delivery and carriers for stem cell delivery systems.

Polyacrylic and polymethacrylic acids, in combination with polymers such as polyacrylamide, provide the ability for controlled and sustained drug delivery since they represent pHand temperature responsiveness. In addition, the synthesis techniques can be used to develop a higher level of supramolecular structures as the interpenetrating polymer networks - as bulk hydrogels or micro-/nanogels. They can provide the opportunity to organize and build up state-ofthe- art carriers for different types of drugs, thus providing the ability to control their loading capacity and drug release performance. This flash review aims to summarize the efforts for synthesizing such interpenetrating polymer networks and their properties and to demonstrate the authors' contributions to this field.

Background: Various types of nano-formulations are being developed and tested for the delivery of the ocular drug. They also have anatomical and physiological limitations, such as tear turnover, nasal lachrymal waste, reflex squinting, and visual static and dynamic hindrances, which pose challenges and delay ocular drug permeation. As a result of these limitations, less than 5% of the dose can reach the ocular tissues. Objective: The basic purpose of designing these formulations is that they provide prolonged retention for a longer period and can also increase the course time. Methods: To address the aforementioned issues, many forms of polymeric micelles were developed. Direct dissolving, dialysis, oil-in-water emulsion, solvent evaporation, co-solvent evaporation, and freeze-drying are some of the methods used to make polymeric nano micelles. Results: Their stability is also very good and also possesses reversible drug loading capacity. When the drug is given through the topical route, then it has very low ocular bioavailability. Conclusion: The definition and preparation process of polymeric micelles and anti-inflammatory drugs used in uveitis and the relation between uveitis and micelles are illustrated in detail.

Background: Herbal preparations with low oral bioavailability have a fast first-pass metabolism in the gut and liver. To offset these effects, a method to improve absorption and, as a result, bioavailability must be devised. Objective: The goal of this study was to design, develop, and assess the in vivo toxicity of polyherbal phytosomes for ovarian cyst therapy. Methods: Using antisolvent and rotational evaporation procedures, phytosomes containing phosphatidylcholine and a combination of herbal extracts (Saraca asoca, Bauhinia variegata, and Commiphora mukul) were synthesized. For a blend of Saraca asoca, Bauhinia variegata, and Commiphora mukul, Fourier-transform infrared spectroscopy (FTIR), preformulation investigations, qualitative phytochemical screening, and UV spectrophotometric tests were conducted. Scanning electron microscopy (SEM), zeta potential, ex vivo release, and in vivo toxicological investigations were used to examine phytosomes. Results: FTIR studies suggested no changes in descriptive peaks in raw and extracted herbs, although the intensity of peaks was slightly reduced. Zeta potential values between -20.4 mV to - 29.6 mV suggested stable phytosomes with an accepted particle size range. Percentage yield and entrapment efficiency were directly correlated to the amount of phospholipid used. Ex vivo studies suggested that the phytosomes with low content of phospholipids showed good permeation profiles. There was no difference in clinical indications between the extract-loaded phytosomes group and the free extract group in in vivo toxicological or histopathological examinations. Conclusion: The findings of current research work suggested that the optimized phytosomes based drug delivery containing herbal extracts as bioenhancers has the potential to improve the bioavailability of hydrophobic extracts.

Background: Formulations of eprosartan mesylate with a surfactant, like Kolliphor HS 15, an oil phase like Labrafil M 1944 CS, and a cosurfactant Transcutol HP by employing a liquid self-microemulsifying drug delivery system (SMEDDS) after screening several vehicles have been studied. Objective: This study aimed to prepare a liquid self-microemulsifying drug delivery system for increasing the solubility and bioavailability of a poorly water-soluble eprosartan mesylate. Methods: The micro-emulsion unit, achieved through the phase diagram and augmented with the central-composite design (CCD) surface response process, was adjusted into SMEDDS by lyophilization using sucrose as a cryoprotective agent. Particle size, self-emulsification time, polydispersion index (PDI), zeta potential, differential scanning calorimeter (DSC) screening, in-vitro drug release, and in-vivo pharmacokinetics were the essential features of the formulations. The subsequent DSC experimentation indicated that the drug was integrated into S-SMEDDS. Eprosartan mesylate loaded SMEDDS formulation showed greater in-vitro and in-vivo drug release than conventional solid doses. Results: SMEDDS has reported effectiveness in reducing the impact of pH of eprosartan mesylate, thereby improving its release efficiency. The HPLC method was successfully implemented to assess eprosartan mesylate concentration in Wister rat plasma after oral administration of commercial tablet EM, SMEDDS, and eprosartan mesylate. The pharmacokinetics parameters for rats were Cmax 1064.91 ± 225 and 1856.22 ± 749 ngmL^-1, Tmax 1.9 ± 0.3 hr, and 1.2 ± 0.4 hr and AUC0~t were 5314.36 ± 322.61 and 7760.09 ± 249 ng/ml hr for marketed tablets and prepared SSMEDDS, respectively. When determined by AUC0~1, the relative bioavailability of eprosartan mesylate S-SMEDDC was 152.09 ± 14.33%. Conclusion: The present study reports the formulation of a self-microemulsifying drug delivery system for enhancing the solubility and bioavailability of a poorly water-soluble eprosartan mesylate in an appropriate solid dosage form.

Background: Paccai eruvai formulation has been widely used in traditional Siddha practice to treat ulcerous wounds due to the content of potentially active compounds. Objective: The present study aimed to determine the enhancement potency of wound healing of nanogels containing Paccai eruvai in an incision and excision wound models. Methods: Paccai eruvai nanogel was synthesized using the high-energy milling method, and characterization and enhancement of the wound healing potential of Paccai eruvai nanogel were assessed. Results: Reportedly, Paccai eruvai nanogel has been produced successfully and its chemical properties confirmed, and physical properties characterized. Paccai eruvai nanogel showed homogeneity, green color, transparency, and an average size of 19.73 nm. We observed a significant reduction of wound area (p<0.001) in the Paccai eruvai nanogel-treated rats. The percentage of wound contraction on the 16th day was higher than the traditional formulation and nitrofurazone treatment. Notably, a lesser epithelialization period (14.33 days) and higher hydroxyproline content were observed in the 10% Paccai eruvai nanogel rats. We found that 10 % Paccai eruvai nanogel treatment increased tensile strength suggesting a better therapeutic indication. Conclusion: The present findings indicate that Paccai eruvai nanogel significantly contributes wound healing activities with the enhancement of collagen synthesis, wound contraction, and wound tensile strength.

Introduction: In recent years, plant-mediated synthesis of silver nanoparticles has evolved as a promising alternative to traditional synthesis methods. In addition to producing silver nanoparticles with diverse biomedical potential, the biosynthesis approach is known to be inexpensive, rapid, and environmentally friendly. Objective: This study was aimed at synthesizing silver nanoparticles using ethanolic stem and root bark extracts of Khaya grandifoliola and highlighting the biomedical potential of the nanoparticles by evaluating their antioxidant, antidiabetic and anticholinesterase effects in vitro. Methods: Silver nanoparticles were prepared using ethanolic stem and root bark extracts of K. grandifoliola as precursors. The biogenic silver nanoparticles were characterized using UV-visible spectroscopy, fourier transform infrared spectroscopy, scanning electron microscopy and energydispersive X-ray analysis. Furthermore, 2,2-Diphenyl-1-picrylhydrazyl radical scavenging, ferric ion reducing antioxidant power, and nitric oxide scavenging assays were used to determine the antioxidant property of the nanoparticles. The antidiabetic potential of the nanoparticles was determined by evaluating their inhibitory effect on the activity of α-amylase and α-glucosidase. The anticholinesterase potential of the nanoparticles was determined by assessing their inhibitory effect on the activity of acetylcholinesterase and butyrylcholinesterase. Results: UV-visible spectroscopy showed surface plasmon resonance bands between 425 and 450 nm. Scanning electron microscopy revealed almost round nanoparticles with a maximum size of 91 nm. Fourier transform infrared spectroscopy affirmed the role of the phytoconstituents present in K. grandifoliola as reducing and stabilizing agents. The biogenic silver nanoparticles showed remarkable antioxidant, antidiabetic, and anticholinesterase effects. Conclusion: Biogenic silver nanoparticles could be useful in biomedical and pharmacological applications.

Background: Delivery systems with low immunogenicity and toxicity are believed to enhance the efficacy of specific targeted drug delivery to cancer cells. Exosomes are potential natural nanosystems that can enhance the delivery of therapeutic agents for targeted cancer therapy. Objective: This study provides a precise effect size of exosomes as nanovesicles for in vitro delivery of anticancer agents. Methods: In this systematic review and meta-analysis, the efficacy of exosomes as nanocarriers for the delivery of therapeutic molecules was investigated using the random-effects model. We did comprehensive literature searches through CINAHL, Cochrane, PubMed, Scopus, and Science Direct of in vitro studies that reported exosomes as delivery systems for cancer therapy. Results: After the screening of eligible articles, a total of 50 studies were enrolled for the metaanalysis. The results showed that cancer cells treated with exosome-loaded anticancer agents for at least 6 h significantly decreased cell viability and increased cytotoxicity with the standardized mean difference (SMD) of -1.47 (-2.18, -0.76; (p<0.0001) and -1.66 (-2.71, -0.61; p<0.002). Exosomes effectively delivered drugs and exogenous miRNAs, siRNAs, viruses, and enzymes to cancer cells in vitro. Conclusion: This meta-analysis provides evidence of exosomes as efficient nanocarriers for the delivery of anticancer drugs.